The PSG 32nd Annual Meeting

34th Annual Symposium

June 2-5, 2022

Phoenix, AZ

Exhibitors & Sponsors

Sponsorship

Diamond Level

We are a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Over the last 30 years, we have built an extensive expertise in product development. Initially, we were a stand-alone development organization, then a U.S. subsidiary of Shire plc and, in late 2005, we became Supernus Pharmaceuticals, Inc.

Gold Level

At Sunovion, we strive to serve and create value for patients every day. By developing innovative therapies that treat serious Central Nervous System (CNS) conditions, science leads the way—guiding us to a healthier tomorrow.

We are advancing therapies to tackle some of the most challenging psychiatric and neurological disorders that impact the lives of millions of people worldwide. As a patient-centered company, we focus on improving the quality of life for those living with serious CNS conditions. Within a decade, we have introduced several new treatment options and will continue expanding our portfolio to enable better outcomes for those we serve. Innovation today, healthier tomorrows.

ACADIA Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders. Our efforts are focused in Parkinson’s disease psychosis, for which we have the first and only treatment approved by the FDA, as well as clinical development programs in Alzheimer’s disease psychosis, negative symptoms of schizophrenia, chronic pain and Rett Syndrome.

Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases with a targeted approach to neuroscience that combines expertise in neurocircuitrywith a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson’s, epilepsy, schizophrenia, and dementia-related apathy. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations, or potential acquisitions. For more information, visitwww.cerevel.com.

Silver Level

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids, as well as over a dozen mid-to late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because patients deserve brave science.

Grants

Exhibitors